Abiopharma

🔍 Fleury Patrick (Executive)

Company: TERAWULF INC. (WULF)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Acquired 327,054 shares of Common stock, $0.001 par value per share (Direct)
  Date: 2026-04-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,532,054.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 121,612 shares of Common stock, $0.001 par value per share (Direct)
  Date: 2026-04-14 | Code: D | equity_swap_involved: 0 | shares_owned_after: 3,410,442.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 327,054 shares of Performance-Based Restricted Stock Units (Derivative)
  Date: 2026-04-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 981,162.00 | transaction_form_type: 4 | Footnotes: F3, F4, F1, F1

Footnotes:

• F1: The performance stock units vested in accordance with their terms upon the achievement of specified performance goals between the grant date and the third anniversary of January 2, 2026, subject to the Reporting Person's continued employment or service with the Issuer through such date.
• F2: The disposition is due to withholding to cover taxes, as a result of the Reporting Person's election of net settlement of performance stock units, which vest in accordance with their terms upon the achievement of specified performance goals between the grant date and the third anniversary of January 2, 2026, subject to the Reporting Person's continued employment or service with the Issuer through each such date.
• F3: Each performance stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• F4: The remaining performance stock units will vest in accordance with their terms upon the achievement of specified performance goals between the grant date and the third anniversary of January 2, 2026, subject to the Reporting Person's continued employment or service with the Issuer through each such date.